코아스템켐온, ALS 치료제 '뉴로나타-알주' 품목허가 변경 승인

This approval represents a significant milestone in autologous stem cell treatments for neurodegenerative diseases like ALS. The conditional authorization reflects a regulatory shift towards balancing early patient access with rigorous post-market validation, potentially accelerating the commercialization of regenerative medicine.